A survey of issues regarding ADR and ADR reporting amongst doctors in Delhi

International Journal of Risk and Safety in Medicine

Volumn 17, Issue 1-2, 2005, Pages 39-46

  Bhatia, Ashima ^a   Kapoor, Upender ^a,b   Tayal, Girish ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b NONE   (India)

Author keywords

Adverse drug reactions; Awareness; Monitoring; Reporting

Indexed keywords

CHI SQUARE TEST; DRUG SURVEILLANCE PROGRAM; HEALTH CARE DELIVERY; HUMAN; INDIA; MEDICAL PRACTICE; PHYSICIAN; REVIEW; RISK ASSESSMENT;

EID: 23944441156     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. American Society of Hospital Pharmacists, Top-priority actions for preventing adverse drug events in hospitals, Am. J. Health-Syst. Pharm. 53 (1996), 747-751.
2. A. Arnold, S. Welch and A. Coutlas, Development of an adverse drug reaction reporting scheme, Hosp. Pharmacist 7(3) (2000), 79-80.
3. J.S. Bapna, U. Tekur and C.D. Tripathi, An introduction to the concept of essential drugs and rational drug use for training of doctors, in: International Experience in Rational Use of Drugs, R.R. Choudhary, ed., The College of Public Health, Chulalongkorn, University, Bangkok, 1997, pp. 79-84.
4. D.W. Bates, D.J. Cullen, N. Laird, L.A. Peterson, S.D. Small, D. Servi et al., Incidence of adverse drug events and potential adverse drug events. Implications for prevention, JAMA 274 (1995), 29-34.
5. D.W. Bates, N. Spell, D.J. Cullen, E. Burdick, N. Laird, L.A. Petersen et al., The costs of adverse drug events in hospitalized patients, JAMA 277(4) (1997), 307-311.
6. D.C. Classen, S.L. Pestotnik, R.S Evans, J.F. Lloyd and J.P. Burke, Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality, JAMA 277 (1997), 301-306.
7. T.R. Einarson, Drug related hospital admissions, Ann. Pharmacotherapy 27 (1993), 832-840.
8. R.S. Evans, S.L. Pestotnik and D.C. Classen, Preventing adverse drug events in hospitalized patients, Ann. Pharmacother. 28(4) (1994), 523-527.
9. R.S. Evans, S.L. Pestotnik and D.C. Classen, Prevention of adverse drug events through computerised surveillance, in: Proc. Annu. Symp. Comput. Appl. Med. Care, 1992, pp. 437-441.
10. N.J. Gogtay, S.S. Dalvi and N.A. Kshirsagar, Safety monitoring: An Indian perspective, International Journal of Risk & Safety in Medicine 16 (2003/2004), 21-30.
11. J. Gruber, G. Blaies and J. Byars, Implementing a formal adverse drug reaction monitoring Program in a long-term care and assisted living setting, The Consultant Pharmacist 16.
12. J. Lazarou, B.H. Pomeranz and P.N. Corey, Incidence of adverse reactions in hospitalized patients; A meta analysis of prospective studies, JAMA 279 (1998), 1200-1205.
13. L.L. Leape, D.W. Bates and D.J. Cullen, Systems analysis of adverse drug events, JAMA 274(1) (1995), 35-43.
14. L.L. Leape, T.A. Brennan, N. Laird, A.G. Lawthers, A.R. Localio, B.A. Barnes et al., The nature of adverse events in hospitalized patients. Results of Havard Medical Practice Study II, N. Engl. J. Med. 324 (1991), 377-384.
15. T.S. Lesar, L. Briceland and D.S. Stein, Factors related to errors in medication prescribing, JAMA 277(4) (1997), 312-317.
16. M.S. Phillips, Quality assurance through adverse drug reactions monitoring reporting: Improving hypnotic prescribing, Hosp. Pharm. 25 (1990), 246-248.
17. B.S. Prince, C.M. Geotz, T.L. Rihn and M. Oisky, Drug related emergency department visits and hospital admissions, Am. J. Hosp. Pharm. 49 (1992), 1696-1700;
18. B.S. Prince, C.M. Geotz, T.L. Rihn and M. Oisky, Am. J. Hosp. Pharm. (2001), 558-562.
19. W.B. Smucker and J.R. Kontak, Adverse drug reactions causing hospital admissions in elderly population: Experience with decision algorithm, J. Am. Board Family Practice 3 (1990) 105-109.
20. M.D.B. Stephens, Definition and classification of adverse drug reaction terms, in: The Detection of New Adverse Drug Reactions, M.D.B. Stephens, J.C.C. Talbot and P.A. Rotledge, eds, Macmillan, London, 1998, pp. 32-44.
21. World Health Organisation, International drug monitoring: The role of national centres. Report of a WHO meeting, World Health Organ. Tech. Rep. Ser. 498 (1972), 1-25.